Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,410.59 -339.85 (-0.51%) CMC Crypto 200
1,426.91 +12.15 (+0.86%)
Precigen, Inc. (PGEN)
After hours:
| Previous close | 1.3800 |
| Open | 1.4000 |
| Bid | 1.3900 x 600 |
| Ask | 1.4200 x 600 |
| Day's range | 1.3900 - 1.4500 |
| 52-week range | 0.8400 - 1.8800 |
| Volume | |
| Avg. volume | 1,014,414 |
| Market cap | 348.487M |
| Beta (5Y monthly) | 1.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis (RRP) and bring together RRP patients and their caregivers to encourage new conne
- PR Newswire
Precigen Reports Full Year 2023 Financial Results and Business Updates
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2023 financial results and business updates.
- PR Newswire
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Cantor Fitzgerald will be hosting a virtual fireside chat with Precigen on Monday, March 25, 2024 at 1:00 PM ET to discuss the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). The event will be hosted by Jennifer Kim, Biotechnology Analyst at Canto
